Alcide Barberis
CEO
M
Mabylon
Mabylon AG develops human-derived antibodies using B-cell screening technologies to create high-quality therapeutic candidates for neurological diseases and severe allergies. By focusing on immune repertoires from patients with relevant conditions, the company aims to enhance understanding of disease mechanisms and improve treatment efficacy.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$21.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Developing effective treatments for neurological diseases and severe allergies is challenging due to the complexity of disease mechanisms and the difficulty in identifying high-affinity, disease-relevant antibodies. Traditional antibody discovery methods often struggle to produce candidates with the desired specificity and therapeutic potential.
Solution
Mabylon AG leverages its B-cell screening technology and expertise in immunology and neurology to discover and engineer human-derived antibodies for therapeutic applications. The company focuses on sourcing immune repertoires from patients with relevant conditions to identify antibodies that target disease-relevant epitopes. Mabylon's platform enables rapid cloning and expression of monoclonal antibodies, facilitating the selection of functionally superior therapeutic candidates. By focusing on human-derived antibodies, Mabylon aims to gain insights into human biology and develop treatments with improved efficacy and safety profiles.
Target Audience
Mabylon's primary target audience includes pharmaceutical and biotechnology companies seeking novel antibody therapeutics for neurological diseases and severe allergies.
Features
- B-cell screening technology for identifying and cloning natural, human-derived antibodies
- High-throughput antibody-expression platforms for rapid production of monoclonal antibodies
- Access to diverse sources of immune repertoires, focusing on patients with relevant conditions
- Functional assays for selecting antibodies with desired therapeutic properties
- Antibody engineering capabilities for optimizing antibody characteristics
- Focus on validated targets in allergy, inflammation, and neurology